Member Info for PaulBrains

And **a lot** has happened since then

How could that possibility be right?

More like......

£11.9m + £11.5m (after expenses)

less three months cash burn - £3.3m

c.£20m at end of January I'd think. Which gives runway to late 2025.

It's on the back of the Snowdrop report - not orchestrated.

Placing price of 11p is acting as a magnet sadly - just the way it tends to work.

You need to read the RNS properly.

notes the recent decline in its share price and confirms it is unaware of any **operational or company-specific reason** for this share price movement

Surely - if they have them on trial they don't need to buy them? Simple point but may well be true.

Seems like an odd move without anything material.

Stated in the RNS - timing of working capital. Hard to know how much is related to that though. I'd suspect almost all of it given lack of comment further.

Very significant - barely any reaction stateside but think LSE will actually wake up tomorrow.

No, released as that's the requirement on management if material changes happen.

It's "UP TO"

**UP TO** AND **POTENTIAL** - thus there's a chance they don't get anything more.

You're ignoring the debt ENQ has - so for the purposes of a fair comparison you need to use Enterprise Value which is Market Cap + Net Debt.

I think my point was I wouldn't expect until at least tomorrow.

The October video appeared on 16th November FWIW.

Well below OO price now. The right answer was to wait and buy in the market.

Retest of 5p more likely.

My guess would an upfront payment of somewhere closer to £500m then a 10% royalty but more likely they'll just buy Scancell out for a 100% premium on share price - assuming it's closer to c. £500m market cap by then.

Well they have just sold another machine so reminder that revenue will kick the cash can down the round

It's pretty well priced with a high chance of failure at the moment. That RNS in my view reduces chance of failure and makes financing more likely.